Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir and ABT-450: terminator of hepatitis C virus?

World journal of gastroenterology - 7 Jun 2013

Zeng Qing-Lei, Zhang Ji-Yuan, Zhang Zheng, Wang Li-Feng, Wang Fu-Sheng

Abstract excerpt

Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C. Unfortunately, not all patients can achieve a sustained virologic response (SVR) with this regimen. SVR rates are approximately 80% in patients with hepatitis C virus (HCV) genotype 2, 3, 5 and 6 and 40%-50% in patients with genotype 1 and 4. Therefore, strategies to improve SVR rates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclopropanes
Share to Interleukins
Share to Lactams, Macrocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Macrocyclic Compounds

Share to Patient Selection

Share to Sofosbuvir

Share to Sulfonamides

Share to Uridine Monophosphate

Source

Open in PubMed Open full text

Identifiers

PMID: 23745021
DOI: 10.3748/wjg.v19.i21.3199
PMCID: PMC3671071

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir and ABT-450: terminator of hepatitis C virus?PMID 23745021Read ↗

New antiviral agents for the treatment of hepatitis C: ABT-450.Semantic proximity Read ↗

Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.Semantic proximity Read ↗

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

A Synopsis of Hepatitis C Virus Treatments and Future PerspectivesSemantic proximity Read ↗

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Semantic proximity Read ↗

What is the role of sofosbuvir in treating hepatitis C infection?Semantic proximity Read ↗

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.Semantic proximity Read ↗

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.Semantic proximity Read ↗

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.Semantic proximity Read ↗

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.Semantic proximity Read ↗

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.